Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).

J Clin Oncol · 2021 · PMC8189598 · PMID 33891472

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The HR for PFS in the ITT population was 0.92 (95% CI, 0.79 to 1.07, stratified log-rank P = .28), which did not reach statistical significance (Fig 2 A).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.